Blockchain Registration Transaction Record

Oncotelic's AI-Driven Cancer Research Gains National Recognition Through NetworkNewsWire

Oncotelic Therapeutics featured in NetworkNewsWire for AI-driven cancer research targeting glioblastoma & pancreatic cancer. Clinical-stage biopharma with 500+ patents advancing transformative treatments.

This development matters because it represents significant progress in treating some of the most aggressive and difficult-to-treat cancers, including glioblastoma and pancreatic cancer, which have historically had poor survival rates. For patients and families affected by these devastating diseases, Oncotelic's innovative approach combining AI, nanomedicine, and advanced clinical strategies offers new hope where traditional treatments have failed. The company's extensive patent portfolio and strategic partnerships suggest these therapies could reach patients faster, potentially transforming cancer care and improving survival outcomes for thousands of people worldwide.